| First Author | Grochowska KM | Year | 2023 |
| Journal | EMBO J | Volume | 42 |
| Issue | 4 | Pages | e112453 |
| PubMed ID | 36594364 | Mgi Jnum | J:348186 |
| Mgi Id | MGI:7437271 | Doi | 10.15252/embj.2022112453 |
| Citation | Grochowska KM, et al. (2023) Jacob-induced transcriptional inactivation of CREB promotes Abeta-induced synapse loss in Alzheimer's disease. EMBO J 42(4):e112453 |
| abstractText | Synaptic dysfunction caused by soluble beta-amyloid peptide (Abeta) is a hallmark of early-stage Alzheimer's disease (AD), and is tightly linked to cognitive decline. By yet unknown mechanisms, Abeta suppresses the transcriptional activity of cAMP-responsive element-binding protein (CREB), a master regulator of cell survival and plasticity-related gene expression. Here, we report that Abeta elicits nucleocytoplasmic trafficking of Jacob, a protein that connects a NMDA-receptor-derived signalosome to CREB, in AD patient brains and mouse hippocampal neurons. Abeta-regulated trafficking of Jacob induces transcriptional inactivation of CREB leading to impairment and loss of synapses in mouse models of AD. The small chemical compound Nitarsone selectively hinders the assembly of a Jacob/LIM-only 4 (LMO4)/ Protein phosphatase 1 (PP1) signalosome and thereby restores CREB transcriptional activity. Nitarsone prevents impairment of synaptic plasticity as well as cognitive decline in mouse models of AD. Collectively, the data suggest targeting Jacob protein-induced CREB shutoff as a therapeutic avenue against early synaptic dysfunction in AD. |
